Prof. Michal Lotem, MD.
Head of the Center for Melanoma and Cancer Immunotherapy, Dept. of Oncology.
The Melanoma and Cancer Immunotherapy Center at the Hadassah Hospital, and Lotem’s lab as the leader of the center is at the forefront of innovative research and patient treatment. As such, the Center has a significant impact on the management of cancer patients through the development of novel approaches to improve current immunotherapies. T Cell Therapy is one such immunotherapy that represents a highly promising and robust approach for the treatment of many cancers.
During the last years, the lab has been studying the SLAM (signaling lymphocyte activation molecule) family of receptors in the anti-cancer immune response. Our data, recently published, suggests that SLAMF6 may play a role in the immune regulation of lymphocyte responses. We hypothesize that splice variants may be involved, and may, therefore, have potential significance for developing the future novel immunotherapies for cancer.
We are enthusiastic about this new direction in light of Prof. Lotem’s deep involvement with the treatment of melanoma patients with new immunotherapies just entering clinical use. It is now clear that triggering the immune system is beneficial for patients, but the success rates are still too low and the need to target more than one modulatory molecule is apparent.
Our team includes clinicians and basic and translational researchers who, in addition to extensive immunological experience, have the benefit of proximity to the clinic and immediate access to clinical data and patient-derived tissues.